In this video, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, talks about delivering personalized therapy for patients with thoracic malignancies. From the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Prof. Fennell outlines potential targets such as EGFR, ALK and PD-L1 expression, and how developing tailored therapy can improve the outcomes of relapsed patients.
Personalized therapy in thoracic malignancies
